OpenResearchAlpha

Journal of Immunotherapy · 12 Nov 2026

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients With Metastatic Melanoma

Meghan J. Mooradian, Yujin Hoshida, Anita Giobbie-Hurder, Joseph I. Clark, Jeffrey A. Sosman, Kim Margolin, Xuesong Gu, Simon T. Dillon, Shijia Zhu, Tongqi Qian, Jesse S.S. Novak, Elizabeth I. Buchbinder, Jean-Christophe Pignon, Theodore Logan, Henry Koon, Marc S. Ernstoff, Thomas Olencki, Asim Amin, Thomas Hutson, John Stewart, Rupal Bhatt, James W. Mier, Howard Kaufman, Michael B. Atkins, Nikhil I. Khushalani, Sabina Signoretti, Towia A. Libermann, David F. McDermott, Ryan J. Sullivanh-index 39

0
Citations
no database records one yet
0
Citations in 2026
so far
39
Leading author's h-index
Ryan J. Sullivan, in QAI's scholar index
46
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

High-dose aldesleukin (HD-IL2) produces durable responses in a portion of patients with melanoma. In the modern era, HD-IL2 is a key component of tumor infiltrating lymphocyte (TIL) therapy and newer forms of IL-2 have shown promise across tumor types. The Select trial aimed to validate biomarkers of HD-IL2 responsiveness. First, we retrospectively identified a proinflammatory (Class 2) gene expression profile (GEP) associated with HD-IL2 responsiveness. Prospective biomarker discovery was then performed in patients with metastatic melanoma receiving HD-IL2 with a primary objective to validate Class 2 GEP as a predictor of efficacy. Additional analyses examined potential serum and tissue protein biomarkers. Retrospective GEP data (n=28) demonstrated a response benefit in GEP Class 2 versus Class 1 subgroup (ORR: 86% vs. 38%; P =0.0384). In the prospective cohort with GEP data (n=152), HD-IL2 resulted in an ORR of 17.7%, a median PFS of 2.4 months (95% CI: 2.1–2.8 mo) and median OS of 21.2 months (95% CI: 19.0–25.5 mo). Using gene set enrichment analysis, Class 2 GEP tumors had a higher response (21% vs. 12%; P =0.2678) and 2-year OS (37.2% vs. 22.4% P =0.1229) in comparison to Class 1 but did not meet predefined levels of significance. Serum proteomic analysis highlighted that low C-reactive protein was associated with response. In conclusion, although Class 2 GEP did not meet the predefined measure of significance, it correlated with response and lower CRP levels were associated with improved outcomes. Building on this work, future biomarker studies are primed to guide contemporary IL-2 administration

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Ryan J. Sullivan has the highest h-index among the authors (39).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (29)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (46)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 26 more references

A free account opens the rest of the citing papers and references on every paper’s page.